{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T16:03:27Z","timestamp":1765382607106,"version":"build-2065373602"},"reference-count":94,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Medicine, Pharmacy, Science, and Technology \u201cGeorge Emil Palade\u201d of Targu Mures","award":["511\/1\/17 January 2022"],"award-info":[{"award-number":["511\/1\/17 January 2022"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Background: The objective of our study was to investigate the impact of mineralocorticoid receptor antagonists (MRAs), such as spironolactone, administrated early after cardiac transplantation on the occurrence of acute graft rejection (AGR) in the first 2 years post-transplant. Methods: This retrospective research was conducted in the Emergency Institute for Cardiovascular Diseases and Transplantation of Targu Mures, Romania. After applying the inclusion criteria, between January 2011 and December 2023, 36 patients fit the study design. Using Cox proportional hazards regression and Kaplan\u2013Meier curves, we determined the time-to-event distribution, for which the first episode of AGR was considered an event, with a significance threshold of 0.05. Results: The 1-year rate of AGR was 38.9% and was 47.2% at 2 years, with a 2-year mortality of 11.1%. The interpretation of the Cox regression indicated that early initiation of spironolactone represents a protective factor against the 2-year AGR (HR: 0.263; 95%CI: 0.076\u20130.922; p = 0.037 by the log-rank test). Conclusions: These results might suggest a possible benefit of the early administration of spironolactone after a heart transplant, but further prospective studies need to be performed for the validation of our findings.<\/jats:p>","DOI":"10.3390\/biomedicines13051164","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T04:21:23Z","timestamp":1747023683000},"page":"1164","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Effect of Early Spironolactone Administration on 2-Year Acute Graft Rejection in Cardiac Transplant Patients"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4004-9648","authenticated-orcid":false,"given":"Dragos-Florin","family":"Baba","sequence":"first","affiliation":[{"name":"Department of Cell and Molecular Biology, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540142 Targu Mures, Romania"},{"name":"Emergency Institute for Cardiovascular Diseases and Transplant, 540136 Targu Mures, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina","family":"Danilesco","sequence":"additional","affiliation":[{"name":"Targu-Mures County Hospital, 540072 Targu Mures, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Horatiu","family":"Suciu","sequence":"additional","affiliation":[{"name":"Emergency Institute for Cardiovascular Diseases and Transplant, 540136 Targu Mures, Romania"},{"name":"Department of Surgery, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540142 Targu Mures, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1488-3329","authenticated-orcid":false,"given":"Calin","family":"Avram","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics and Biostatics, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540142 Targu Mures, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marius Mihai","family":"Harpa","sequence":"additional","affiliation":[{"name":"Emergency Institute for Cardiovascular Diseases and Transplant, 540136 Targu Mures, Romania"},{"name":"Department of Surgery, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540142 Targu Mures, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6297-0378","authenticated-orcid":false,"given":"Mircea","family":"Stoian","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Intensive Care, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540139 Targu Mures, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5536-3938","authenticated-orcid":false,"given":"Diana-Andreea","family":"Moldovan","sequence":"additional","affiliation":[{"name":"Emergency Institute for Cardiovascular Diseases and Transplant, 540136 Targu Mures, Romania"},{"name":"Department of Family Medicine, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540142 Targu Mures, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9413-7803","authenticated-orcid":false,"given":"Laurentiu","family":"Huma","sequence":"additional","affiliation":[{"name":"Department of Cell and Molecular Biology, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540142 Targu Mures, Romania"},{"name":"Emergency Institute for Cardiovascular Diseases and Transplant, 540136 Targu Mures, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Rusu","sequence":"additional","affiliation":[{"name":"Emergency Institute for Cardiovascular Diseases and Transplant, 540136 Targu Mures, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tunde","family":"Pal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540136 Targu Mures, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6862-4926","authenticated-orcid":false,"given":"Adina","family":"Stoian","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540136 Targu Mures, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca-Ileana","family":"Sin","sequence":"additional","affiliation":[{"name":"Department of Cell and Molecular Biology, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540142 Targu Mures, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"104191","DOI":"10.1016\/j.lpm.2023.104191","article-title":"End-stage heart failure: The future of heart transplant and artificial heart","volume":"53","author":"Bounader","year":"2024","journal-title":"Presse Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S1388-9842(00)00141-0","article-title":"More \u2018malignant\u2019 than cancer? Five-year survival following a first admission for heart failure","volume":"3","author":"Stewart","year":"2001","journal-title":"Eur. J. Heart Fail."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s11897-019-00432-3","article-title":"Updates on Heart Transplantation","volume":"16","author":"Shah","year":"2019","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1309\/713JVR58EF916DN5","article-title":"Cause of death and sudden cardiac death after heart transplantation. An autopsy study","volume":"119","author":"Alexander","year":"2003","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e14756","DOI":"10.1111\/ctr.14756","article-title":"Validation of cause of death classification after heart transplantation and cause-specific life expectancy compared to the general population","volume":"36","author":"Gjesdal","year":"2022","journal-title":"Clin. Transplant."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1146\/annurev.pathol.3.121806.151449","article-title":"Graf vascular disase:Immune response meets the vessel wall","volume":"4","author":"Mitchell","year":"2009","journal-title":"Annu. Rev. Pathol."},{"key":"ref_7","first-page":"549","article-title":"Long-term outcome following heart transplantation: Current perspective","volume":"7","author":"Wilhelm","year":"2015","journal-title":"J. Thorac. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"565","DOI":"10.4070\/kcj.2018.0189","article-title":"The Past, Present and Future of Heart Transplantation","volume":"48","author":"Kim","year":"2018","journal-title":"Korean Circ. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1161\/CIR.0000000000000093","article-title":"Antibody-mediated rejection in cardiac transplantation: Emerging knowledge in diagnosis and management: A scientific statement from the American Heart Association","volume":"131","author":"Colvin","year":"2015","journal-title":"Circulation"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00467-008-1020-x","article-title":"Mechanism of cellular rejection in transplantation","volume":"25","author":"Ingulli","year":"2010","journal-title":"Pediatr. Nephrol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/TP.0000000000000950","article-title":"Impact of Rabbit Antithymocyte Globulin Dose on Long-term Outcomes in Heart Transplant Patients","volume":"100","author":"Aliabadi","year":"2016","journal-title":"Transplantation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/tri.12480","article-title":"Thymoglobulin induction in heart transplantation: Patient selection and implications for maintenance immunosuppression","volume":"28","author":"Zuckermann","year":"2015","journal-title":"Transpl. Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e15326","DOI":"10.1111\/ctr.15326","article-title":"Induction therapy in heart transplantation: A systematic review and network meta-analysis for developing evidence-based recommendations","volume":"38","author":"Kugathasan","year":"2024","journal-title":"Clin. Transplant."},{"key":"ref_14","first-page":"e20240060","article-title":"Real-world cost-effectiveness analysis of thymoglobulin versus no induction therapy in kidney transplant recipients at low risk of graft loss","volume":"47","author":"Bessa","year":"2025","journal-title":"J. Bras. Nefrol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1111\/ajt.15342","article-title":"Rabbit anti-thymocyte globulin for the prevention of acute rejection in kidney transplantation","volume":"19","author":"Alloway","year":"2019","journal-title":"Am. J. Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.transproceed.2006.10.030","article-title":"Induction therapy in lung transplantation: Initial single-center experience comparing daclizumab and antithymocyte globulin","volume":"39","author":"Lischke","year":"2007","journal-title":"Transplant. Proc."},{"key":"ref_17","first-page":"79","article-title":"Relationship between Post-kidney Transplantation Antithymocyte Globulin Therapy and Wound Healing Complications","volume":"3","author":"Pourmand","year":"2012","journal-title":"Int. J. Organ Transplant. Med."},{"key":"ref_18","first-page":"243","article-title":"Thymoglobulin-induced severe cardiovascular reaction and acute renal failure in a patient scheduled for orthotopic liver transplantation","volume":"72","author":"Busani","year":"2006","journal-title":"Minerva Anestesiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.trre.2015.02.005","article-title":"Immunosuppressive therapies after heart transplantation--The balance between under- and over-immunosuppression","volume":"29","year":"2015","journal-title":"Transplant. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/j.1600-6143.2006.01290.x","article-title":"Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report","volume":"6","author":"Kobashigawa","year":"2006","journal-title":"Am. J. Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e14081","DOI":"10.1111\/ctr.14081","article-title":"Beta-blocker therapy in heart transplant recipients: A review","volume":"34","author":"Masarone","year":"2020","journal-title":"Clin. Transplant."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/j.ijcard.2012.12.089","article-title":"Long-term prognostic value of elevated heart rate one year after heart transplantation","volume":"168","author":"Castel","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e14696","DOI":"10.1111\/ctr.14696","article-title":"Angiotensin-converting enzyme inhibitor therapy after heart transplant: From molecular basis to clinical effects","volume":"36","author":"Masarone","year":"2022","journal-title":"Clin. Transplant."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ahj.2020.01.003","article-title":"Long-term clinical outcomes with use of an angiotensin-converting enzyme inhibitor early after heart transplantation","volume":"222","author":"Arashi","year":"2020","journal-title":"Am. Heart J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e003265","DOI":"10.1161\/CIRCHEARTFAILURE.116.003265","article-title":"Impact of Statin Use After Heart Transplantation: A Meta-Analysis","volume":"9","author":"Vallakati","year":"2016","journal-title":"Circ. Heart Fail."},{"key":"ref_26","first-page":"42","article-title":"The role of statins in patients after heart transplantation","volume":"12","author":"Szczurek","year":"2015","journal-title":"Kardiochir. Torakochirurgia Pol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1002\/ehf2.12784","article-title":"Statin intensity and risk for cardiovascular events after heart transplantation","volume":"7","author":"Golbus","year":"2020","journal-title":"ESC Heart Fail."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Baba, D.-F., Suciu, H., Avram, C., Danilesco, A., Moldovan, D.A., Rauta, R.C., Huma, L., and Sin, I.A. (2023). The Role of Preoperative Chronic Statin Therapy in Heart Transplant Receipts-A Retrospective Single-Center Cohort Study. Int. J. Environ. Res. Public Health, 20.","DOI":"10.3390\/ijerph20043471"},{"key":"ref_29","first-page":"251","article-title":"Normality assessment, few paradigms and use cases","volume":"30","author":"Avram","year":"2022","journal-title":"Romanian Rev. Lab. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e14713","DOI":"10.1111\/petr.14713","article-title":"Efficacy and safety of single-dose anti-thymocyte globulin versus basiliximab induction therapy in pediatric kidney transplant recipients: A retrospective comparative cohort study","volume":"28","author":"Custodio","year":"2024","journal-title":"Pediatr. Transplant."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Hussain, Y., and Khan, H. (2022). Immunosuppressive Drugs. Encycl. Infect. Immun., 726\u2013740.","DOI":"10.1016\/B978-0-12-818731-9.00068-9"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1182\/asheducation-2017.1.639","article-title":"Extracorporeal photopheresis: Cellular therapy for the treatment of acute and chronic graft-versus-host disease","volume":"2017","author":"Schneiderman","year":"2017","journal-title":"Hematol. Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/ajh\/hpaa137","article-title":"Aldosterone, Inflammation, Immune System, and Hypertension","volume":"34","author":"Ferreira","year":"2021","journal-title":"Am. J. Hypertens."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Huma, L., Suciu, H., Avram, C., Suteu, R.-A., Danilesco, A., Baba, D.-F., Moldovan, D.-A., and Sin, A.-I. (2024). Implications of Preoperative C-Reactive Protein Levels in Heart Transplant Patients\u2014A Single-Center Retrospective Study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13237466"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Baba, D.-F., Suciu, H., Avram, C., Gyorgy, M., Danilesco, A., Huma, L., and Sin, I.A. (2023). Elevated Levels of Neutrophil-to Monocyte Ratio Are Associated with the Initiation of Paroxysmal Documented Atrial Fibrillation in the First Two Months after Heart Transplantation: A Uni-Institutional Retrospective Study. J. Cardiovasc. Dev. Dis., 10.","DOI":"10.3390\/jcdd10020081"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Baba, D.-F., Suciu, H., Huma, L., Avram, C., Danilesco, A., Moldovan, D.A., Opincar, A.S., and Sin, A.I. (2023). Platelet-to-Albumin Ratio: The Prognostic Utility in the Prediction of 2-Month Postoperative Heart Transplant Complications. J. Cardiovasc. Dev. Dis., 10.","DOI":"10.3390\/jcdd10060241"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4049\/jimmunol.0802886","article-title":"Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity","volume":"184","author":"Herrada","year":"2010","journal-title":"J. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/HYPERTENSIONAHA.113.02883","article-title":"Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes","volume":"63","author":"Amador","year":"2014","journal-title":"Hypertension"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/00007890-197107000-00006","article-title":"The role of macrophages in skin allograft rejection: I. histochemical studies during first-set rejection","volume":"12","author":"Poulter","year":"1971","journal-title":"Transplantation"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5763430","DOI":"10.1155\/2019\/5763430","article-title":"The Evolving Roles of Macrophages in Organ Transplantation","volume":"2019","author":"Li","year":"2019","journal-title":"J. Immunol. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/ajt.17206","article-title":"Targeting IL-6 to prevent cardiac allograft rejection","volume":"22","author":"Miller","year":"2022","journal-title":"Am. J. Transplant."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-Fern\u00e1ndez, B., Rubio-Navarro, A., Cortegano, I., Ballesteros, S., Al\u00eda, M., Cannata-Ortiz, P., Olivares-\u00c1lvaro, E., Egido, J., de Andr\u00e9s, B., and Gaspar, M.L. (2016). Aldosterone Induces Renal Fibrosis and Inflammatory M1-Macrophage Subtype via Mineralocorticoid Receptor in Rats. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0145946"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e16092","DOI":"10.7717\/peerj.16092","article-title":"Macrophage polarization in tissue fibrosis","volume":"11","author":"Yang","year":"2023","journal-title":"PeerJ"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jacc.2011.11.036","article-title":"Cardiac fibrosis in human transplanted hearts is mainly driven by cells of intracardiac origin","volume":"59","author":"Pichler","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.kisu.2021.11.006","article-title":"The role of mineralocorticoid receptor activation in kidney inflammation and fibrosis","volume":"12","author":"Luther","year":"2022","journal-title":"Kidney Int. Suppl."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s40472-021-00331-4","article-title":"IL-6 Directed Therapy in Transplantation","volume":"8","author":"Miller","year":"2021","journal-title":"Curr. Transplant. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3892\/etm.2022.11296","article-title":"Spironolactone alleviates myocardial fibrosis via inhibition of Ets-1 in mice with experimental autoimmune myocarditis","volume":"23","author":"Wang","year":"2022","journal-title":"Exp. Ther. Med."},{"key":"ref_48","first-page":"206","article-title":"Overview of Non-Vitamin K Oral Anticoagulants","volume":"68","author":"Militaru","year":"2020","journal-title":"Farm. J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.47162\/RJME.61.4.20","article-title":"Predictors of early and sustained virological response of viral hepatitis C","volume":"61","author":"Ghenea","year":"2020","journal-title":"Rom. J. Morphol. Embryol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jchf.2020.11.010","article-title":"Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF","volume":"9","author":"Ferreira","year":"2021","journal-title":"JACC Heart Fail."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"F519","DOI":"10.1152\/ajprenal.00606.2018","article-title":"Spironolactone reduces oxidative stress in living donor kidney transplantation:a randomized controlled trial","volume":"317","author":"Marino","year":"2019","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"F529","DOI":"10.1152\/ajprenal.00025.2019","article-title":"Effect of spironolactone for 1 yr on endothelial function and vascular inflammation biomarkers in renal transplant recipients","volume":"317","author":"Mortensen","year":"2019","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"S295","DOI":"10.1016\/j.healun.2019.01.741","article-title":"Treatment with a Statin or Spironolactone is Associated with a Reduced Risk for Primary Graft Dysfunction and Mortality","volume":"38","author":"Peled","year":"2019","journal-title":"J. Heart Lung Transplant."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41440-020-0428-y","article-title":"Sodium-induced inflammation-an invisible player in resistant hypertension","volume":"43","author":"Sadowski","year":"2020","journal-title":"Hypertens. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/ajt.15163","article-title":"Neutrophil extracellular trap fragments stimulate innate immune responses that prevent lung transplant tolerance","volume":"19","author":"Scozzi","year":"2019","journal-title":"Am. J. Transplant."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"101434","DOI":"10.1016\/j.trim.2021.101434","article-title":"Diphenyleneiodonium ameliorates acute liver rejection during transplantation by inhibiting neutrophil extracellular traps formation in vivo","volume":"68","author":"Liu","year":"2021","journal-title":"Transpl. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"101286","DOI":"10.1016\/j.trim.2020.101286","article-title":"A potential role of neutrophil extracellular traps (NETs) in kidney acute antibody mediated rejection","volume":"60","year":"2020","journal-title":"Transpl. Immunol."},{"key":"ref_58","first-page":"II289","article-title":"Early Doppler echocardiographic dysfunction is associated with an increased mortality after orthotopic cardiac transplantation","volume":"94","author":"Ross","year":"1996","journal-title":"Circulation"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Sciaccaluga, C., Fusi, C., Landra, F., Barilli, M., Lisi, M., Mandoli, G.E., D\u2019Ascenzi, F., Focardi, M., Valente, S., and Cameli, M. (2022). Diastolic function in heart transplant: From physiology to echocardiographic assessment and prognosis. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.969270"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e14109","DOI":"10.1111\/ctr.14109","article-title":"Comparing outcomes for infiltrative and restrictive cardiomyopathies under the new heart transplant allocation system","volume":"34","author":"Griffin","year":"2020","journal-title":"Clin. Transplant."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.healun.2022.12.004","article-title":"The 2023 International Society for Heart and Lung Transplantation Guidelines for Mechanical Circulatory Support: A 10- Year Update","volume":"42","author":"Saeed","year":"2023","journal-title":"J. Heart Lung Transplant."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/jocs.16329","article-title":"Trends and outcomes following total artificial heart as bridge to transplant from the UNOS database","volume":"37","author":"Coyan","year":"2022","journal-title":"J. Card. Surg."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1007\/s00268-014-2639-3","article-title":"Organ shortage: The greatest challenge facing transplant medicine","volume":"38","author":"Shafran","year":"2014","journal-title":"World J. Surg."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa2201422","article-title":"Genetically Modified Porcine-to-Human Cardiac Xenotransplantation","volume":"387","author":"Griffith","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e12800","DOI":"10.1111\/xen.12800","article-title":"First transplantation of a pig heart from a multiple gene-modified donor, porcine cytomegalovirus\/roseolovirus, and antiviral drugs","volume":"30","author":"Denner","year":"2023","journal-title":"Xenotransplantation"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"12592","DOI":"10.3389\/ti.2024.12592","article-title":"Clinical Pig Heart Xenotransplantation-Where Do We Go From Here?","volume":"37","author":"Cooper","year":"2024","journal-title":"Transpl. Int."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"135","DOI":"10.21037\/acs.2017.12.02","article-title":"The future of cardiac transplantation","volume":"7","author":"Koomalsingh","year":"2018","journal-title":"Ann. Cardiothorac. Surg."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1126\/science.aad1191","article-title":"Genome-wide inactivation of porcine endogenous retroviruses (PERVs)","volume":"350","author":"Yang","year":"2015","journal-title":"Science"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1016\/S0140-6736(15)60261-6","article-title":"Ex-vivo perfusion of donor hearts for human heart transplantation (PROCEED II): A prospective, open-label, multicentre, randomised non-inferiority trial","volume":"385","author":"Ardehali","year":"2015","journal-title":"Lancet"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1016\/S0140-6736(15)60038-1","article-title":"Adult heart transplantation with distant procurement and ex-vivo preservation of donor hearts after circulatory death: A case series","volume":"385","author":"Dhital","year":"2015","journal-title":"Lancet"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.healun.2016.07.004","article-title":"Functional assessment and transplantation of the donor heart after circulatory death","volume":"35","author":"Messer","year":"2016","journal-title":"J. Heart Lung Transplant."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Elezaby, A., Dexheimer, R., and Sallam, K. (2022). Cardiovascular effects of immunosuppression agents. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.981838"},{"key":"ref_73","first-page":"2624","article-title":"Cardiac allograft vasculopathy: Current review and future research directions","volume":"117","author":"Pober","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"706","DOI":"10.2174\/157016110792006923","article-title":"Impact of immunosuppressive drugs on the development of cardiac allograft vasculopathy","volume":"8","author":"Dandel","year":"2010","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e025507","DOI":"10.1161\/JAHA.122.025507","article-title":"Characteristics, Predictors, and Outcomes of Early mTOR Inhibitor Use After Heart Transplantation: Insights From the UNOS Database","volume":"11","author":"Kampaktsis","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/01.mot.0000186082.47623.76","article-title":"Enhanced immunosuppression induced by targeted mutation of cytotoxic T lymphocyte antigen 4-immunoglobulin","volume":"10","author":"Kokko","year":"2005","journal-title":"Curr. Opin. Organ Transplant."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1080\/14656566.2020.1753698","article-title":"The pharmaceutical management of cardiac allograft vasculopathy after heart transplantation","volume":"21","author":"Spitaleri","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.mrrev.2006.11.002","article-title":"Circulating free DNA in plasma or serum as biomarker of carcinogenesis: Practical aspects and biological significance","volume":"635","author":"Gormally","year":"2007","journal-title":"Mutat. Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1161\/CIRCULATIONAHA.120.049098","article-title":"Cell-Free DNA to Detect Heart Allograft Acute Rejection","volume":"143","author":"Shah","year":"2021","journal-title":"Circulation"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Vejpongsa, P., Torre-Amione, G., Marcos-Abdala, H.G., Kumar, S., Youker, K., Bhimaraj, A., and Nagueh, S.F. (2022). Long term development of diastolic dysfunction and heart failure with preserved left ventricular ejection fraction in heart transplant recipients. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-07888-9"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s12410-010-9055-3","article-title":"Cellular and Functional Imaging of Cardiac Transplant Rejection","volume":"4","author":"Wu","year":"2011","journal-title":"Curr. Cardiovasc. Imaging Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e033672","DOI":"10.1161\/JAHA.123.033672","article-title":"Diastolic Filling in Patients After Heart Transplantation Is Impaired Due to an Altered Geometrical Relationship Between the Left Atrium and Ventricle","volume":"13","author":"Nelsson","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/phar.2928","article-title":"The efficacy and safety of sodium-glucose cotransporter-2 inhibitors in solid organ transplant recipients: A scoping review","volume":"44","author":"Mreyoud","year":"2024","journal-title":"Pharmacotherapy"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e069641","DOI":"10.1136\/bmjopen-2022-069641","article-title":"Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): Protocol for a randomised controlled trial","volume":"13","author":"Raven","year":"2023","journal-title":"BMJ Open."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.2249","article-title":"Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: Rationale and design of the DELIVER trial","volume":"23","author":"Solomon","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Kommu, S., and Berg, R.L. (2024). The Efficacy and Safety of Sacubitril\/Valsartan Compared to Valsartan in Patients with Heart Failure and Mildly Reduced and Preserved Ejection Fractions: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J. Clin. Med., 13.","DOI":"10.3390\/jcm13061572"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2459\/JCM.0000000000001411","article-title":"Sacubitril\/valsartan reduces cardiac decompensation in heart failure with preserved ejection fraction: A meta-analysis","volume":"24","author":"Basile","year":"2023","journal-title":"J. Cardiovasc. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.jacc.2020.12.057","article-title":"Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function","volume":"77","author":"Beldhuis","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e018827","DOI":"10.1161\/JAHA.120.018827","article-title":"Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension","volume":"9","author":"Tsujimoto","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Baba, D.F., Suciu, H., Avram, C., Harpa, M.M., Stoian, M., Moldovan, D.A., Huma, L., Rusu, G., Pal, T., and Danilesco, A. (2024). The Impact of Heart Failure Chronic Treatment Prior to Cardiac Transplantation on Early Outcomes. Medicina, 60.","DOI":"10.3390\/medicina60111801"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1183\/09031936.00136408","article-title":"Small studies: Strengths and limitations","volume":"32","author":"Hackshaw","year":"2008","journal-title":"Eur. Respir. J."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/5\/1164\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:30:30Z","timestamp":1760031030000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/5\/1164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,10]]},"references-count":94,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["biomedicines13051164"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines13051164","relation":{},"ISSN":["2227-9059"],"issn-type":[{"type":"electronic","value":"2227-9059"}],"subject":[],"published":{"date-parts":[[2025,5,10]]}}}